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Abstract
Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary
stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel. We hypothesized that serotonin
antagonism reduces high on-treatment platelet reactivity. Whole blood impedance aggregometry was performed with
arachidonic acid (AA, 0.5 mM) and adenosine diphosphate (ADP, 6.5 mM) in addition to different concentrations of serotonin
(1–100 mM) in whole blood from 42 CAD patients after coronary stent placement and 10 healthy subjects. Serotonin
increased aggregation dose-dependently in CAD patients who responded to clopidogrel treatment: After activation with
ADP, aggregation increased from 33.761.3% to 40.962.0% in the presence of 50 mM serotonin (p,0.05) and to 48.262.0%
with 100 mM serotonin (p,0.001). The platelet serotonin receptor antagonist ketanserin decreased ADP-induced
aggregation significantly in clopidogrel low-responders (from 59.963.1% to 37.463.5, p,0.01), but not in clopidogrel
responders. These results were confirmed with light transmission aggregometry in platelet-rich plasma in a subset of
patients. Serotonin hence increased residual platelet reactivity in patients who respond to clopidogrel after coronary stent
placement. In clopidogrel low-responders, serotonin receptor antagonism improved platelet inhibition, almost reaching
responder levels. This may justify further investigation of triple antiplatelet therapy with anti-serotonergic agents.
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Introduction
In myocardial infarction - the critical event in coronary artery
disease (CAD) - plaque rupture initiates platelet activation
resulting in atherothrombotic coronary artery occlusion [1].
Percutaneous coronary intervention with stent placement is the
standard of care treatment for patients with critical CAD [2,3].
Implantation of a coronary stent further stimulates the adhesion
and activation of platelets, which makes a highly efficient
inhibition of platelet activation mandatory until endothelialization
of the stent is complete [4]. Current guidelines recommend dual
antiplatelet therapy for these patients, consisting of the lifelong
administration of acetylsalicylic acid (ASA, aspirin - cyclooxygen-
ase inhibition) in combination with an adenosine diphosphate
(ADP) P2Y12 receptor antagonist for the first 12 months [2,3]. In
acute coronary syndrome the newer P2Y12 receptor antagonists
ticagrelor and prasugrel are preferred, but clopidogrel remains the
standard substance when ticagrelor or prasugrel are contraindi-
cated or unavailable and in patients undergoing elective stenting.
An important clinical problem is hypo-responsiveness to
clopidogrel [5,6]. Clopidogrel is a prodrug and must be
metabolized in intestines and liver to produce an active metabolite
that binds the P2Y12 receptor [7]. In March 2010, the Food and
Drug Administration added a boxed warning to the label of
clopidogrel to highlight its reduced effectiveness in poor meta-
bolizers. Approximately 30% of patients are considered poor
responders as evaluated by ADP-induced platelet aggregation
[8,9,10]. Apart from absorption and receptor reactivity, genetic
and drug-induced variations in cytochrome P450 activity are
responsible for the inter-individual variability in clopidogrel
responsiveness [11]. High on-treatment platelet reactivity to
ADP is associated with adverse clinical event occurrence, but the
wide variety of definitions of residual platelet reactivity has only
recently been addressed by a consensus statement [12]. To date, it
is not clear which measure of platelet reactivity and which cut-off
points should be used.
Light transmission aggregometry (LTA) is largely considered as
the gold standard to evaluate platelet function with respect to
pharmacological platelet inhibition, but is poorly standardized
[12,13]. For LTA, platelet-rich plasma (PRP) is prepared by
centrifugation and stimulated by adding a platelet agonist. The
increase of transmitted light is proportional to the formation of
aggregates under stirring conditions. The level of platelet
aggregation in LTA predicted the early outcome after elective
coronary stent placement in 802 patients treated with clopidogrel
[14]. Whole blood impedance aggregometry, like e.g. with the
point-of-care assay MultiplateH measures the increase in imped-
ance due to attachment of platelets to electrodes [15]. A study with
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multiple electrode aggregometry (MEA) with Multiplate is
equivalent to other assays in identifying patients at risk for stent
thrombosis [16].
Serotonin is a weak platelet activator promoting hemostasis by
enhancing platelet alpha granule release and by enhancing
plasmatic coagulation [17,18,19,20]. Together with ADP, serotonin
isstoredinplateletdensegranules(atmillimolarconcentrations)and
released upon platelet activation, locally reaching micromolar levels
at sites of coronary atherothrombosis [21,22,23]. Released
serotonin is also a potent vasoconstrictor of coronary arteries with
damaged endothelium [24]. Serotonin antagonism as well as
platelet serotonin depletion by treatment with selective serotonin
reuptake inhibitors have both been associated with a reduction in
arterial thrombogenicity [17,25,26]. Therefore, serotonin antago-
nism in addition to established therapies might be a promising
approach to improve the treatment of CAD patients. This concept
was proposed as triple antiplatelet therapy, but to our knowledge
has not yet been evaluated systematically. In consequence, we
hypothesized that serotonin antagonism may reduce high on-
treatment platelet reactivity in ASA- and clopidogrel-treated
patients. We used MEA in whole blood from CAD patients who
had received a coronary stent within the past 1–3 days to test this
hypothesis and confirmed the results with LTA. We found first that
addition of exogenous serotonin increased platelet aggregation in
blood from patients who responded well to ASA and clopidogrel
treatment. Secondly, in vitro serotonin receptor antagonism with
ketanserin reduced high on-treatment platelet reactivity in clopido-
grel low-responders.
Materials and Methods
Patient enrollment and ethics statement
This pilot study examined the ex vivo effects of serotonin and a
serotonin receptor antagonist on platelets from patients who were
treated with ASA and clopidogrel after coronary stent placement.
The protocol complied with the Declaration of Helsinki and was
approved by the Ethics Committee of the University of Freiburg,
Germany. The study was planned prospectively. Participants were
considered eligible for enrollment if they were .18 years of age.
CAD patients gave verbal informed consent for additional ex vivo
measurements with routinely acquired platelet aggregometry
blood samples (which was documented in a log sheet) and written
consent was acquired retrospectively to comply with ethical
guidelines. Healthy control subjects and CAD patients donating
an additional blood sample for LTA gave written informed
consent before sample acquisition. CAD patients receiving ASA
and clopidogrel were recruited consecutively from the local
Department of Cardiology from November 4
th, 2009 through
December 2
nd, 2010 and CAD patients receiving ASA only were
recruited from November 20
th, 2011 through December 29
th,
2011. Depression and current medication with serotonin reuptake
inhibitors were exclusion criteria. Thrombocytopenia #100,000/
mm
3 was also an exclusion criterion. CAD patients had received a
loading dose of 600 mg clopidogrel and at least 300 mg ASA prior
to coronary angiography according to standard operating
procedure at the local institution. Patients then received 75 mg
clopidogrel and 100 mg ASA once daily and compliance was
documented. A blood sample was taken on day 1–3 after stent
placement, while the patients were still hospitalized. Acute
coronary syndrome patients who had received treatment with a
glycoprotein IIb/IIIa inhibitor were excluded. CAD patients
treated with ASA only had not undergone coronary angiography
and were not exposed to clopidogrel prior to blood sampling.
Control subjects were healthy and without current medication.
Control subjects were not included if they had taken ASA or any
other non-steroidal anti-inflammatory drug within the prior 7
days.
A power calculation for an alpha or 0.05 yielded a necessary
sample size of at least 10 per group to detect a difference in mean
aggregation of 9.5% with an assumed standard deviation of 7%
with a power of 80% (G*Power 3.0.10, Heinrich Heine University,
Duesseldorf, Germany). Between 15 and 40% of patients were
considered poor responders to clopidogrel treatment in several
studies applying similar criteria as in our study (see below) [8,9,10].
We therefore envisioned including 45 CAD patients in order to
have a group of approximately 10 clopidogrel low-responders.
Two CAD patients were excluded from the study because the
platelet aggregation response to TRAP was below the pre-defined
threshold (see below) and 1 CAD patient withdrew informed
consent.
Materials
Serotonin hydrochloride, ketanserin, sarpogrelate hydrochlo-
ride, and Prostaglandin (Pg) E1 were obtained from Sigma-Aldrich
(Munich, Germany). Thrombin receptor activating peptide-6
(TRAP), arachidonic acid (AA), and ADP were obtained from
Verum Diagnostica (Munich, Germany). Blood collection tubes
were purchased from Sarstedt (Nuernbrecht, Germany).
Sample acquisition
A 5.2 ml blood sample was taken from all study participants for
multiple electrode aggregometry (MEA) and anticoagulated with
0.045 mg/ml hirudin. For LTA, 30 ml of blood were taken from
all control subjects and a third of the enrolled CAD patients
(randomly chosen) and anticoagulated with 0.011 mol/l trisodium
citrate. MEA and LTA were performed within 2 h after sample
acquisition.
Whole blood impedance aggregometry
Hirudinized blood was diluted with an equal volume of normal
saline and kept under stirring conditions at 37uC in a Multiplate
analyzer (Verum Diagnostica, Munich, Germany). Samples were
then incubated with the indicated concentrations of serotonin,
ketanserin, or vehicle (0.001% ascorbic acid and 1:1,000 DMSO)
for 1 min. Finally, the platelet agonist was added at standardized
final concentrations: 32 mM TRAP, 0.5 mM AA, 6.5 mM ADP, or
vehicle. MEA curves from two electrode pairs were recorded for
each sample and the area under the curves (AUC) was averaged.
Blood samples showing a response to TRAP of #450 AU/min did
not meet the criteria for a sufficient positive platelet aggregation
control and were excluded from further analysis (4.4% of the
examined samples; reasons may have been delayed sample analysis
or unreported use of other antiplatelet agents). To ensure optimal
comparability of the effects of serotonergic stimulation, the
aggregation responses were normalized to the response to TRAP
in all samples from each study participant (denoted as % of
TRAP).
Definition of low-responder status
Definition of clopidogrel low-responder status remains a matter
of debate and several groups have suggested different approaches,
resulting in a consensus statement that provided definitions for
different platelet function tests in 2010 [12,27]. In accordance with
this statement we defined clopidogrel low-responsiveness as an
area under the MEA curve of $468 AU/min after ADP
stimulation [12,27]. This corresponded to $48% of maximal
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(while all responders were ,48%). To ensure comparability, low-
responsiveness in LTA was therefore also defined as maximal
aggregation $48% of maximal response to thrombin receptor
activation.
Light transmission aggregometry
LTA was chosen as a gold standard for comparison with MEA
findings using the same platelet agonist concentrations as
described above. One third of the recruited CAD patients treated
with ASA and clopidogrel (n=15) and all CAD patients treated
with ASA only and control subjects were asked to donate an
additional 30 ml of blood, which was refused by 2 CAD patients.
Platelet-rich plasma (PRP) was obtained from citrated blood by
centrifugation at 100 g for 10 min and adjusted to a platelet count
of 2.5610
8/ml with platelet-poor plasma (obtained by centrifuga-
tion at 1,000 g for 5 min). PRP was re-calcified with 1 mM CaCl2
and incubated with serotonin, ketanserin, or vehicle under stirring
conditions for 1 min at 37uC. Platelet agonists were added as
described above in MEA and LTA traces were recorded for
15 min. Maximal aggregation was defined as % light transmission
compared to platelet-poor plasma.
Measurement of serotonin release
After performing MEA, the supernatant (hirudinized whole
blood devoid of platelet aggregates in case of platelet activation)
was aspirated from the Multiplate cuvettes in a subset of 13 CAD
patients. To avoid additional platelet activation by the following
centrifugation steps, blood was incubated with 5 mM EDTA and
4 mg/ml PgE1 for 5 min. Cell-free plasma was prepared by
centrifugation at 1,000 g for 5 min followed by 16,000 g for 5 min
and stored at 280uC. Serotonin concentration was measured with
a high-sensitivity ELISA (Labor Diagnostika Nord, Hamburg,
Germany).
Statistical Analysis
Results are reported as mean and standard error of the mean.
Contingency tables for clinical characteristics were analyzed with
Fisher’s exact test. One-way ANOVA followed by Bonferroni’s
multiple comparison test or unpaired t-test were used to compare
quantification variables between three or two groups, respectively.
All statistical tests were two-sided and a P value of ,0.05 was
interpreted to denote statistical significance. The statistical analysis
was performed with GraphPad Prism 4.0 (GraphPad Software
Inc., La Jolla, CA, USA).
Results
Study subjects
The 42 included CAD patients who were treated with ASA and
clopidogrel showed a typical risk profile and 57% presented with
acute coronary syndrome. Two thirds of these patients received at
least one drug-eluting stent. There were no significant differences
in the frequency of smoking, hypertension, dyslipidemia, Diabetes
mellitus and ACS between clopidogrel responders and low-
responders (Table 1). The group of CAD patients who were
treated with ASA only was well matched with the group of CAD
patients treated with ASA and clopidogrel. Control subjects were
younger and healthy.
Platelet aggregation traces
Incubation with 30 mM TRAP (used as the reference positive
control in this study) resulted in an increase in impedance in MEA
(reflected by the AUC, Fig. 1A) and induced visible platelet
aggregate formation under stirring conditions in LTA (increasing
light transmission, Fig. 1B). The increase in light transmission after
treatment with 6.5 mM ADP was reversible, especially in
clopidogrel-treated patients, as has consistently been reported
before [28,29]. Serotonin at different concentrations alone
induced only small increases in light transmission that were also
quickly reversible (Fig. 1C), but enhanced the response to ADP in
both, MEA and LTA.
Serotonin increases residual platelet reactivity
To test whether exogenous serotonin influenced residual platelet
reactivity in patients treated with ASA and clopidogrel, we
measured the AUC in MEA after stimulation with the depicted
agonists in all study subjects. In healthy control subjects, in-
cubation with vehicle, serotonin (50 mM), AA (0.5 mM), and ADP
(6.5 mM) induced 17.161.0%, 23.861.4%, 80.864.2%, and
74.164.2% of maximal (i.e. TRAP-induced) aggregation, respec-
tively (Figure 2A). Serotonin did not further enhance AA- or ADP-
induced aggregation and ketanserin did not inhibit AA-induced
Table 1. Baseline clinical characteristics of CAD patients treated with ASA only and CAD patients treated with ASA and
clopidogrel.
Variable/parameter
ASA only
(n=9)
Clopidogrel low-responders
(n=12)
Clopidogrel responders
(n=30)
P (ASA only vs.
ASA+clopidogrel)
P (clopidogrel low-
responders vs. responders)
Age (years) Mean 6 SD 73697 3 614 67612 0.274 0.144
Male gender 7 (78) 9 (75) 18 (60) 0.699 0.485
Smokers 4 (44) 3 (25) 15 (50) 1.0 0.180
Hypertension 5 (56) 7 (58) 23 (77) 0.436 0.274
Dyslipidemia 3 (33) 6 (50) 16 (53) 0.465 1.0
Diabetes mellitus 3 (33) 1 (8) 4 (13) 0.137 1.0
Acute coronary syndrome 0 6 (50) 18 (60) 0.732
Drug-eluting stent 0 9 (75) 20 (67) 0.722
Bare-metal stent 0 4 (33) 10 (33) 1.0
Healthy control subjects (n=10) were 3464 years old, 5 were male, 1 smoked and none suffered from the mentioned diseases. P values for the comparison of CAD
patients with ASA only vs. all CAD patients with ASA+clopidogrel and for the comparison of clopidogrel low-responders vs. responders. Number of patients (%), unless
otherwise indicated.
doi:10.1371/journal.pone.0032656.t001
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ADP-induced aggregation by 24.8% in this group. Similar results
were seen in CAD patients who were treated with ASA only
(Fig. 2B), except for the well-inhibited response to AA. Ketanserin
decreased ADP-induced aggregation by 16.4% (not significant).
In the entire cohort of ASA- and clopidogrel-treated CAD
patients, vehicle-, serotonin-, AA-, and ADP-induced aggregation
was 13.662.2%, 22.261.6%, 23.562.1%, and 40.661.9%,
respectively (Figure 2C). Addition of 50 mM serotonin resulted in a
non-significant increase in AA-induced aggregation to 32.262.9%.
ADP-induced aggregationincreaseddose-dependently after addition
of serotonin (up to 51.662.7% with 100 mMs e r o t o n i n ,p ,0.05),
while ketanserin did not induce significant changes. Adding
ketanserin to serotonin-treated samples abolished the enhancement
of ADP-induced aggregation by serotonin entirely (not shown).
These findings indicate that serotonin enhances residual platelet
reactivity in ASA- and clopidogrel-treated patients and that
serotoninantagonismdecreasesADP-inducedaggregationincontrol
subjects.
Serotonin increases ADP-induced platelet aggregation in
clopidogrel responders
We next asked whether clopidogrel responder status influenced
these effects. Serotonin dose-dependently increased ADP-induced
platelet aggregation in clopidogrel responders (Figure 3A): Mean
ADP-induced aggregation was 33.761.3% and 60.063.1% in
clopidogrel responders (n=30) and clopidogrel low-responders
(n=12), respectively, and adding 50 mM serotonin increased
ADP-induced aggregation to 40.962.0% (corresponding to an
increase by 21%, p,0.01) and 62.665.2% (4% increase, not
significant) in these groups. Higher serotonin concentrations
(100 mM) further increased aggregation (to 48.262.0% in
clopidogrel responders, 43% increase, p,0.001, and to
72.563.5% in clopidogrel low-responders, 21% increase, not
significant). Therefore, serotonin enhanced platelet reactivity,
especially in clopidogrel responders.
Ketanserin improves platelet inhibition in clopidogrel
low-responders
To examine whether anti-serotonergic treatment could reduce
enhanced on-treatment platelet reactivity in clopidogrel low-
responders, we blocked the main platelet serotonin receptor 5-
HT2A with the standard antagonist ketanserin. Ketanserin
reduced ADP-induced aggregation in clopidogrel low-responders
only (from 60.063.1% to 37.463.5%, corresponding to a decrease
by 37%, p,0.01, Figure 3B) and did not change ADP-induced
aggregation in clopidogrel responders (Fig. 3A). In a subset of 13
CAD patients treated with ASA and clopidogrel (9 clopidogrel
responders, 4 low-responders), sarpogrelate, a more selective 5-
HT2A receptor antagonist, had a similar effect as ketanserin (not
shown). These results indicate that residual platelet reactivity could
be reduced in clopidogrel low-responders by inhibiting the 5-
HT2A receptor.
LTA reproduces the MEA results
LTA (with PRP) was performed as a gold standard to verify the
MEA findings (whole blood) because to date, not all scientific
groups have accepted whole blood impedance aggregometry as a
standard platelet function test. In healthy control subjects TRAP
treatment resulted in 81.962.5% light transmission, i.e. aggrega-
tion (Fig. 4A), compared to 5.860.8% with vehicle (not shown). In
all CAD patients maximal aggregation was 72.162.1% after
incubation with TRAP (Fig. 4B–D) and 9.661.9% with vehicle
(not shown). Serotonin or ketanserin did not significantly change
ADP-induced aggregation in healthy control subjects (Fig. 4A) or
CAD patients treated with ASA alone (Fig. 4B). On the contrary,
serotonin significantly increased ADP-induced platelet aggregation
in PRP from clopidogrel responders from 35.563.2% to
58.865.1% with 50 mM serotonin (p,0.05) and to 64.867.7%
with 100 mM serotonin (p,0.01, Fig. 4C). Clopidogrel low-
responders showed a non-significant increase in ADP-induced
aggregation with serotonin (Fig. 4D). Ketanserin did not
significantly change ADP-induced aggregation in clopidogrel
responders but induced a non-significant decrease by 46% in the
3 clopidogrel low-responders examined with LTA. In summary,
LTA confirmed the MEA results (with a non-significant trend in
the group with 3 clopidogrel low-responders).
ADP-induced serotonin release is higher in clopidogrel
low-responders
In a subset of 13 CAD patients randomly chosen for measuring
serotonin release, 4 were identified as clopidogrel low-responders.
TRAP induced a significant serotonin release in both, responders
and low-responders (Fig. 5). The TRAP-induced serotonin release
was 12% higher in clopidogrel low-responders as compared to
responders (not significant). ADP induced a 38% higher serotonin
release in low-responders as compared to responders (not
significant). A power calculation estimated a required sample size
of 43 clopidogrel responders and 15 low-responders to reveal
whether this difference is statistically significant.
Discussion
This in vitro study with blood from 42 CAD patients treated with
ASA and clopidogrel, 9 CAD patients treated with ASA only, and
10 healthy control subjects aimed at elucidating the effects of
serotonergic and anti-serotonergic manipulation on platelet
reactivity on top of standard treatment. While the standard of
care treatment after coronary stent implantation includes dual
antiplatelet therapy with ASA and a P2Y12 blocker, anti-
serotonergic agents, namely 5-HT2A receptor blockers, were
Figure 1. Representative aggregation traces. (A) Exemplary
multiple electrode aggregomety traces in whole blood from a
clopidogrel responder after adding the depicted agonists (AUC denotes
area under the curve). (B) Light transmission aggregometry (LTA) with
platelet-rich plasma and the depicted agonists. (C) LTA with vehicle or
serotonin only. The following agonist concentrations were used: 32 mM
TRAP, 6.5 mM ADP, 1, 50, or 100 mM serotonin.
doi:10.1371/journal.pone.0032656.g001
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therapy.
Inhibition of the 5-HT2A receptor, which is the main serotonin
receptor on platelets and arterial smooth muscle cells, with
ketanserin or the newer, more selective agents sarpogrelate and
APD791 prevented occlusive arterial thrombus formation in
several studies [30,31,32,33]. The group around Willerson
established that ketanserin inhibits serotonin-induced cyclic flow
variations caused by platelet aggregation and vasoconstriction in a
canine model of coronary artery stenosis and injury
[34,35,36,37,38,39]. The same group also showed that high levels
of serotonin are released locally during percutaneous coronary
intervention and that serotonin antagonism can enhance coronary
blood flow in patients with CAD [24,40]. Sarpogrelate reduced
restenosis after coronary stenting in a Japanese study of 79 patients
with stable angina [41]. A phase III randomized trial with 1,510
patients showed non-inferiority of sarpogrelate to ASA in
secondary prevention after stroke [42]. In Japan, sarpogrelate
was approved for the treatment of peripheral arterial disease in
1993. We found recently that stimulation of 5-HT2A receptor
induced shedding of the adhesion receptor GPIba from the
platelet surface [43]. In the light of clopidogrel hypo-responsive-
ness and the quest for optimal treatment of CAD patients, the
effects of serotonergic intervention in CAD patients treated with
ASA and clopidogrel are a topic of clinical relevance. Currently,
no clinical trials investigating serotonin antagonism on top of dual
antiplatelet therapy after percutaneous coronary intervention are
registered at clinicaltrials.gov.
We examined whole blood from CAD patients taking ASA and
clopidogrel after coronary stent placement with MEA and found
that 28.5% did not respond adequately to clopidogrel. This is in
accordance with previously published studies applying similar
platelet function testing [12,44]. We found that in clopidogrel
responders, additional serotonin dose-dependently increased ADP-
induced aggregation, i.e. on-treatment platelet reactivity to ADP.
This suggests, that the platelet helper-agonist status of serotonin
can also be extended to CAD patients with dual antiplatelet
therapy [18,22].
Figure 2. Serotonin increases platelet reactivity in whole blood impedance aggregometry. Whole blood from healthy control subjects (A,
n=10), coronary artery disease (CAD) patients treated with ASA alone (B, n=9), and the total study cohort of CAD patients treated with ASA and
clopidogrel (C, n=42) after incubation with the depicted substances. The following agonist/antagonist concentrations were used: 32 mM TRAP,
0.5 mM AA, 50 mM serotonin, 10 mM ketanserin. * p,0.05 in ANOVA followed by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0032656.g002
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reactivity in clopidogrel low-responders. Multiple electrode aggregometry of whole blood from clopidogrel responders (A, mean AUC
6standard deviation after incubation with ADP: 280686 AU/min) and low-responders (B, AUC with ADP 5126127 AU/min) normalized to the
response induced by TRAP. The following agonist/antagonist concentrations were used: 32 mM TRAP, 6.5 mM ADP, 1, 50, or 100 mM serotonin, 10 mM
ketanserin. ** p,0.01 and *** p,0.001 in ANOVA followed by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0032656.g003
Figure 4. Confirmation with light transmission aggregometry. Maximal light transmission, i.e. platelet aggregation in platelet-rich plasma
from healthy control subjects (A), CAD patients treated with ASA alone (B), and clopidogrel responders (C) and low-responders (D) among CAD
patients treated with ASA and clopidogrel. The following agonist/antagonist concentrations were used: 32 mM TRAP, 6.5 mM ADP, 50 mM serotonin,
10 mM ketanserin. * p,0.05 and ** p,0.01 in ANOVA followed by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0032656.g004
Serotonin and Dual Antiplatelet Therapy
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32656Most interestingly, antagonizing the platelet serotonin receptor
with the standard 5-HT2A receptor blocker ketanserin highly
significantly improved platelet inhibition in clopidogrel low-
responders. Ketanserin reduced ADP-induced aggregation in these
patients approximately reaching the levels of clopidogrel responders.
These results allow the hypothesis that clopidogrel hypo-responsive-
ness could be overcome with a serotoninreceptor blocker. A possible
explanation for ketanserin being effective in clopidogrel low-
responders but not responders, is that ADP may induce relevant
serotonin release in clopidogrel low-responders only, because P2Y12
is not sufficiently inhibited in these patients. Indeed, we saw an
increase in serotonin release after incubation with ADP in
clopidogrel low-responders that appeared higher than in responders.
Evaluating whether this increase is statistically significant willrequire
a larger sample size as the one chosen for this pilot study.
The fact that ketanserin did not reduce platelet aggregation
beyond clopidogrel responder levels is suggestive for a favorable
risk profile of triple antiplatelet therapy with anti-serotonergic
agents: the risk for bleeding may not increase. More studies,
especially investigating in vivo administration of serotonin blockers
in addition to standard treatment, are needed to confirm these
results. Several clinicial trials have demonstrated that clopidogel
low-responder status is associated with an unfavorable clinical
outcome (reviewed in [11,44]). Future trials evaluating triple
antiplatelet therapy with anti-serotonergic agents, such as
sarpogrelate or APD791, should particularly address the question
whether morbidity and mortality can be reduced with serotonin
blockers. In addition to suggested beneficial effects on vascular
tone, ischemic tolerance, prevention of coronary restenosis, and
insulin resistance, based on our findings, we hypothesize that this
strategy may particularly improve platelet inhibition without
further increasing bleeding complications [45,46,47].
Limitations
As a single-center study with pilot character, this investigation
included only 42 CAD patients, 12 of whom were clopidogrel low-
responders. Such a small sample size limits the generalization of
our conclusions. Larger studies are warranted to confirm the
findings. We used ketanserin to antagonize the 5-HT2A receptor in
vitro, because it is considered a long-established standard substance.
Clinical use of ketanserin in CAD was promising at first, but has
been discontinued because of an unfavorable risk profile, including
a possible association with the development of diabetes [30,48].
Future trials should therefore focus on the aforementioned newer,
more selective agents, one of which (sarpogrelate) showed similar
results in a subset of samples in our study. While the MEA findings
were largely reproduced with LTA, the improvement of platelet
inhibition in clopidogrel low-responders with ketanserin did not
reach statistical significance with LTA. Only 3 out of the 13 CAD
patients who donated additional blood for LTA measurements
showed clopidogrel hypo-responsiveness and we believe that the
non-significance of this result was mainly due to the particularly
small sample size in this group.
Conclusions
This in vitro study demonstrates that serotonin increases residual
platelet reactivity in patients who respond to ASA and clopidogrel
after coronary stent placement. In clopidogrel low-responders,
serotonin receptor antagonism improves platelet inhibition, almost
reaching responder levels. Further investigation of triple antiplate-
let therapy with anti-serotonergic agents to decrease elevated on-
treatment platelet reactivity therefore appears promising.
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